Shared scheme for assessing drugs for multiple sclerosis :Dealing with uncertainties about cost effectiveness of treatments is difficult problemBMJ 2003; 326 doi: https://doi.org/10.1136/bmj.326.7400.1212-a (Published 29 May 2003) Cite this as: BMJ 2003;326:1212
- David Chadwick, professor of neurology (firstname.lastname@example.org),
- Richard Gray, professor of statistics
- Walton Centre for Neurology and Neurosurgery, University of Liverpool, Liverpool L9 7LJ
- Birmingham Clinical Trials Unit, University of Birmingham, Birmingham B15 2TT
EDITOR—Sudlow and Counsell argue for a trial comparing disease modifying treatments with azathioprine, and placebo as an alternative to the risk sharing scheme, which they believe to be scientifically unsound.1 As independent scientific advisers to the scheme we would like to correct some inaccuracies.
Firstly, patients who have already been prescribed disease modifying treatments will not contribute to the main analyses of cost effectiveness. …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial